BioMarin Pharmaceutical Third Quarter 2026 Conference Call - AMICUS THERAPEUTICS INC

Financial Performance:

• Third-quarter 2026 revenue surpassed $1 billion for the first time in company history, achieving 32% year-over-year growth.
• Metabolic conditions revenue grew 44% year-over-year to $744 million, driven by Gallifold ($152M, up 10%), Pompability and Opfolda ($49M, up 58%), Palinzek (up 2%), and Zimizim (up 18%).
• Voxogo revenue increased 12% year-over-year to $245 million, though a large international order shifted from Q3 to Q4.
• Non-GAAP diluted earnings per share (EPS) for the quarter were $0.23, impacted by $290 million in non-cash IPR&D expenses from the Alesta acquisition.
• Underlying non-GAAP SG&A expenses rose 12% year-over-year, primarily due to the addition of Amicus commercial teams.
• Cost synergies from the Amicus acquisition are ahead of schedule, with the deal expected to be accretive within nine months and full synergy realization ($220 million non-GAAP) targeted for 2028.

Guidance and Future Outlook:

• Updated full-year 2026 total revenue guidance to $3.8 billion–$3.9 billion, down from prior estimates due to a $70 million order deferral by a single international customer and Middle East geopolitical headwinds.
• Updated full-year 2026 non-GAAP diluted EPS guidance to $2.80–$3.10, reflecting the impact of the Alesta and BMN450 deals and adjusted revenue timing.
• The midpoints of the original and updated EPS guidance are effectively unchanged when excluding recent deal impacts, indicating underlying profitability goals are met.
• Anticipate strong growth in 2027, driven by the launch of Voxogo in hypochondroplasia and international expansion, despite Q4 order timing shifts pushing some revenue into Q1 2027.
• Confident that the $220 million in cost synergies will be fully realized by 2028.

Business Segments and Product Lines:

• Metabolic Conditions: Patient counts increased across all brands; Gallifold patient count grew 13% YoY, while Pompability/Opfolda patient count surged 69% YoY, aided by competitor supply constraints.
• Skeletal Conditions: Voxogo patient volume grew 17% globally with 85% retention among US children under two; PDUFA date for hypochondroplasia set for May 30, 2027.
• Pipeline Expansion: Added four new assets in 2026: BMN450 (Phase 1-2 Fabry, potential first subcutaneous ERT), BMN440 (Phase 1-2 hypophosphatasia, oral substrate reduction therapy), BMN430 (new syndrome), and BMN820 (FSGS).
• Voxogo: Expanded approval to three additional international markets; preparing for US/EU launch in hypochondroplasia by focusing on diagnosis, evidence sharing, and payer engagement.
• Pompability/Opfolda: Five-year data presented showing sustained motor and pulmonary function; currently market share leader in four European markets.

Market and Competitive Landscape:

• Biomarin holds a leading position in skeletal conditions and metabolic disorders, leveraging a diversified portfolio to reduce reliance on single products.
• In Pompe disease, competitor supply constraints have accelerated patient switching to Pompability/Opfolda in specific European markets, creating a near-term revenue tailwind.
• In achondroplasia, Voxogo maintains exclusivity for children under two years old in the US, a critical window per international treatment guidelines.
• Management views competitor concerns regarding FGFR2 inhibition safety as hypothetical, citing Voxogo's robust 5,000-patient safety record as the primary differentiator.

Risks and Challenges:

• Order Timing Volatility: A single international customer deferred approximately $70 million in orders from Q4 to Q1 2027, creating revenue recognition uncertainty.
• Geopolitical Headwinds: Prolonged conflict in the Middle East has impacted customer liquidity and cash flow, contributing to the guidance update.
• Development Risks: BMN333 development involves unproven safety regarding FGFR2 inhibition and potential growth plate closure with combination therapies; BMN440 requires proof of mechanism data in 2027.
• Regulatory Uncertainty: FDA approval for Voxogo in hypochondroplasia is pending a PDUFA decision, and future data readouts (BMN333, BMN440) remain critical for program viability.

Management Commentary and Tone:

• Management expressed strong confidence in the diversified portfolio's resilience and the successful integration of the Amicus acquisition.
• Tone was optimistic regarding the pipeline expansion, emphasizing a "focused and deliberate" strategy to add clinical-stage assets.
• Executives acknowledged order timing as the primary driver for guidance adjustments, reinforcing that underlying patient demand remains robust.
• Management highlighted the strategic value of the Amicus deal, noting accelerated synergy realization and the addition of key assets like Gallifold and Pompe therapies.

Analyst Questions and Answers:

• Cost Synergies: Confirmed that Amicus integration synergies are ahead of schedule, with the deal becoming accretive within nine months rather than a full calendar year.
• Pompability/Opfolda Growth: Analysts asked to separate competitor supply-driven growth from organic uptake; management indicated the clinical profile drives switching, but supply shortages accelerated current starts, with revenue benefits building into 2027.
• BMN333 Data Readout: Clarified that the 2027 readout will provide PK/PD (growth velocity) data to support a potential superiority hypothesis against Voxogo, though a non-inferiority or alternate dosing strategy remains a contingency.
• BMN440 Proof of Concept: Defined as demonstrating biomarker activity and pharmacokinetics in Phase 1-2a studies in 2027.
• Order Timing Details: Confirmed the $70 million deferral is primarily international and not related to patient demand; a separate Voxogo order shifted from Q3 to Q4, but the $70M is the key guidance driver.

Other Key Points:

• The Alesta acquisition closed on August 31, 2026, adding BMN440 and contributing to the pipeline expansion strategy.
• Royalty and other revenue streams now include amounts earned from the global settlement with Ascendus.
• Management plans to shift reporting focus from US switching metrics to overall revenue updates for Voxogo in Q4 as the product mix changes with the new indication.
• The company has executed five business development deals over the last two years, demonstrating strong execution across the value chain.